-
Mashup Score: 0
The Clostridioides difficile Health-related Quality-of-Life Questionnaire responses demonstrated patients handled the situation better with specific investigational treatments.
Source: Infection Control TodayCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0
RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
Specific investigational treatments helped the patients handle the recurrent C diff situation better. https://t.co/z7alqR5Wgx #cdiff # Clostridioidesdifficile #rcdi #infectionprevention